Related Experiment Videos
Aspirin in the primary prevention of cardiovascular disease
1Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Insights
Aspirin significantly lowers the risk of heart attack, stroke, and vascular death in patients with existing cardiovascular disease. It also reduces heart attacks in men during primary prevention, with ongoing trials for women.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Preventive Cardiology
Background:
- Cardiovascular diseases (CVD) remain a leading cause of mortality and morbidity worldwide.
- Aspirin is a widely used antiplatelet medication with established roles in secondary CVD prevention.
- The efficacy of aspirin in primary prevention across diverse populations requires ongoing investigation.
Purpose of the Study:
- To synthesize evidence on the efficacy of aspirin in reducing cardiovascular disease risks.
- To evaluate aspirin's benefits in both secondary and primary prevention settings.
- To identify specific patient subgroups that benefit most from aspirin therapy.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs).
- Inclusion of trials across various patient categories, including those with prior CVD events and primary prevention cohorts.
- Analysis focused on outcomes such as nonfatal myocardial infarction, nonfatal stroke, and vascular death.
Main Results:
- Aspirin demonstrated significant reductions in nonfatal myocardial infarction, nonfatal stroke, and vascular death in patients with established cardiovascular disease.
- Benefits were observed in secondary prevention, including post-myocardial infarction and unstable angina.
- In primary prevention, aspirin showed a clear reduction in myocardial infarction incidence among men.
Conclusions:
- Aspirin is effective in reducing major adverse cardiovascular events in secondary prevention.
- Evidence supports aspirin's role in primary prevention for men, with ongoing research for women.
- The use of aspirin should be considered within a comprehensive cardiovascular risk management strategy.
Abstract:
The ability of aspirin to reduce cardiovascular disease risks has been tested in randomized trials in a wide range of patient categories. There are clear benefits of aspirin on nonfatal myocardial infarction, nonfatal stroke, and vascular death among patients with prior manifestations of cardiovascular disease, such as myocardial infarction, unstable angina, and stroke. Aspirin is also beneficial to those in the acute phase of evolving myocardial infarction. In primary prevention, there is a clear reduction in myocardial infarction in men. A large-scale primary prevention trial in women is presently underway.